A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Recruiting

Phase 1

Imetelstat & RuxolitinibA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Sponsor:

Geron Corporation

Code:

NCT05371964

Conditions

Myelofibrosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Imetelstat sodium

Ruxolitinib

Pacritinib

Momelotinib

Fedratinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-19. This information was provided to ClinicalTrials.gov by Geron Corporation on 2025-09-30.